WA
GILD icon

Walsh & Associates’s Gilead Sciences GILD Stock Holding History

Walsh & Associates’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Sell
100
-3
-3% -$395 0.01% 186
2026
Q1 		$14.4K Buy
103
+3
+3% +$420 0.01% 169
2025
Q4 		$12.3K Buy
+100
New +$12.2K 0.01% 177

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Walsh & Associates's GILD Position: Q2 2026 in Review

Walsh & Associates reduced its Gilead Sciences (GILD) stake by 2.9% in Q2 2026, selling an estimated $395 and leaving 100 shares worth $12.6K. The position accounts for 0.01% of the portfolio, ranked #186.

Walsh & Associates first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $14.4K in Q1 2026. 2,260 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Walsh & Associates held 100 shares of Gilead Sciences worth $12.6K as of Q2 2026.
  • Walsh & Associates sold 3 Gilead Sciences shares in Q2 2026, an estimated $395.
  • Gilead Sciences made up 0.01% of Walsh & Associates's portfolio in Q2 2026, its #186 holding.
  • Walsh & Associates first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • Walsh & Associates's Gilead Sciences position peaked at $14.4K in Q1 2026.
  • 2,260 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Walsh & Associates's 13F filing for Q2 2026, filed 21 Jul 2026.